MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.

Authors: Steven Robert Schuster, Saulius Girnius, Rayan Kaedbey, Paola Ochoa, Luděk Pour, Ronan Le Calloch, Tobias S. Slørdahl, Ann De Becker, Fangxin Hong, Margaret Hoyle, Anne Yver, Gregory Finn, Thomas Chalopin

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7568

Source: Full article

---

Abstract

TPS7568